Submitted by Pater Tenebrarum via Acting-Man.com,A Look at the Broader Market’s InternalsWe have previously discussed the stock market’s deteriorating internals, and in light of recent market weakness want to take a brief look at the broader market in the form if the NYSE Index (NYA). First it has to be noted that a majority of the stocks in the NYA […]
At Close: IBB down 2.35% to 342 at May bottom, XBI up 0.64% to 218
—-
Two Hours to Go 2:15p EDT, NASDAQ Down 1.79% at 4792, IBB at $349
Biotech Breakdown: Relief Today Or Another Head Fake?
Biotech stocks are trying to hold the May lows with the IBB at $342 but now at $349. There is bit of buying today and most biotechnology […]
From:
Hunting In Bear Territory
See which stocks are being affected by Social Media
[…]
This article is from –
How to Diversify Your Retirement Portfolio
See which stocks are being affected by Social Media
[…]
A Look at the Broader Market’s InternalsWe have previously discussed the stock market’s deteriorating internals, and in light of recent market weakness want to take a brief look at the broader market in the form if the NYSE Index (NYA). First it has to be noted that a majority of the stocks in the NYA are already in bearish trends. […]
More:
Stocks Rocked: Plunge Lands S&P 500 Back In Negative Territory For 2015
See which stocks are being affected by Social Media
[…]
Momentum stocks are getting crushed. Another generation of Etraders has been fully monetized.Skynet has no one left to milk.IPOs are in free-fallThis morning they were back in 2014, now they’re almost in 2013. They lost a year of gains since this morning…World’s largest IPO (Alibaba)…2nd largest failed IPO (Twitter):Netflix – 8%:The Biotech rally is over…Revenueless BiotechThe top performing IPO for […]
Related CLVSClovis Oncology Could Pass $100 By Year-End: Here’s WhyClovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLCClovis Oncology: Don’t Discount Rociletinib’s Chances Against AZD9291(Seeking Alpha)Related EPZMBenzinga’s Top DowngradesH.C. Wainwright Destroys Epizyme Price Target, Sees ‘No Material Value Drivers’A new report by Mizuho analyst Peter Lawson focuses on biotech stocks with major catalysts […]
By
Timothy Hay
Biography
CONNECT
Biography
Venrock
With biotechnology stocks turning in stellar performances on the Nasdaq Global Exchange and digital-health startups commanding huge funding rounds at high valuations, some are talking about a bubble forming in certain areas of medical technology.But Bryan Roberts of Venrock, who last year logged six successful exits from medical technology investments, doesn’t use the word “bubble.”The industry, he said, is […]
Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]
